Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Precision BioSciences, Inc. - Common Stock (NQ:DTIL)

4.200 -0.100 (-2.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Precision BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Incannex Healthcare (NASDAQ:IXHL) stock rose 164.2% to $60.5 during Tuesday's regular session. Incannex Healthcare's stock is trading at a volume of 664.5K... 
Via Benzinga
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap: Precision BioSciences Q4 Earnings
Precision BioSciences (NASDAQ:DTIL) reported its Q4 earnings results on Tuesday, March 15, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Preview: Precision BioSciences's Earnings
Precision BioSciences (NASDAQ:DTIL) is set to give its latest quarterly earnings report on Tuesday, 2022-03-15. Here's what investors need to know before the announcement.... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Earnings Scheduled For March 15, 2022
Companies Reporting Before The Bell • IDEAYA Biosciences (NASDAQ:IDYA) is likely to report quarterly loss at $0.31 per share on revenue of $8.98 million. • Citi... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers NeuroOne Medical Tech (NASDAQ:NMTC... 
Via Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
Precision BioSciences Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Precision BioSciences (NASDAQ:DTIL) reported Q3 sales of $24.04 million. Earnings fell to a loss of $11.27 million, resulting in a 152.09% decrease from last... 
Via Benzinga
Precision BioSciences Earnings Preview
Precision BioSciences (NASDAQ:DTIL) is set to give its latest quarterly earnings report on Wednesday, 2021-11-10. Here's what investors need to know before the announcement.... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Before 10 am on Wednesday, 99 companies set new 52-week lows. Facts of Interest About Today's 52-Week Lows: Sea (NYSE:SE) was the largest firm by market cap to set a... 
Via Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novavax Shares React to Reports Of Manufacturing Issues With Its COVID-19... 
Via Benzinga
Precision BioSciences, iECURE Ink Licensing Pact For Gene Editing Therapies
Precision BioSciences Inc (NASDAQ: DTIL) and iECURE announced a license and collaboration agreement. Under the agreement iECURE plans to advance Precision's PBGENE-... 
Via Benzinga
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:... 
Via Benzinga
Precision BioSciences, Tiziana Life Ink Foralumab Deal For Cancer Indications
Precision BioSciences Inc (NASDAQ: DTIL) and Tiziana Life Sciences plc (NASDAQ: TLSA) have announced an exclusive license agreement for Tiziana's... 
Via Benzinga
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) AbbVie Inc. (NASDAQ: ABBV... 
Via Benzinga
Precision BioSciences: Q2 Earnings Insights
Shares of Precision BioSciences (NASDAQ:DTIL) rose 0.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 157.14% year... 
Via Benzinga
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
Precision BioSciences Starts Dosing In Blood Cancer Trial With CAR T Therapy
Precision BioSciences Inc (NASDAQ: DTIL) has dosed the first patient in its Phase 1 trial with PBCAR19B in patients with relapsed/refractory (R/R) non-Hodgkin... 
Via Benzinga
60 Biggest Movers From Yesterday
Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its... 
Via Benzinga
44 Stocks Moving In Monday's Mid-Day Session
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software... 
Via Benzinga
Precision BioSciences Moves Higher After Commencing Dosing In PBCAR269A Combination Arm Of Multiple Myeloma Trial
Precision BioSciences Inc (NASDAQ: DTIL) and SpringWorks Therapeutics Inc (NASDAQ: SWTX) have dosed the first patient in the combination arm of Precision... 
Via Benzinga
24 Stocks Moving in Monday's Pre-Market Session
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) rose 28.9% to $114.49 in pre-market trading. Intellia Therapeutics and Regeneron Pharmaceuticals disclosed positive interim... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Enveric Biosciences (NASDAQ:ENVB)... 
Via Benzinga
Precision BioSciences' CD-19 CAR T Therapy Shows Response Rate Of 77% In Lymphoma Trial
Precision BioSciences Inc (NASDAQ: DTIL) announced additional data from its Phase 1/2a study evaluating PBCAR0191, off-the-shelf, allogeneic CAR T candidate... 
Via Benzinga
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19) ESSA Pharma Inc. (NASDAQ:... 
Via Benzinga
Recap: Precision BioSciences Q1 Earnings
Shares of Precision BioSciences (NASDAQ:DTIL) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share were up 36.54% year over year to ($... 
Via Benzinga
Why Precision BioSciences Stock Is Trading Higher Today
Precision BioSciences (NASDAQ: DTIL) shares are trading higher after the company reported its ARCUS platform showed a promising gene editing approach for transthyretin... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.